Clinical Trial Detail

NCT ID NCT02785939
Title Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Palbociclib

Age Groups: adult

No variant requirements are available.